We aim to advance targets and compounds for antiviral drug discovery. The team has expertise in drug discovery from target identification and characterization to Lead Optimization. Using the QCRG Drug Discovery Platform, each of the six Projects will be supported by eight Cores.
Overall, we will follow the traditional, interactive workflow of drug discovery, but each Project and Core includes innovative facets that reflect the unique specialties of the investigators. The 5-year program will deliver 3–6 Optimized Lead molecules to Roche and potentially other partners for preclinical and clinical development. Graduation from each stage of the drug discovery process will follow design criteria that align with pharmaceutical company standards and will be informed by our Target Product Profile for an oral antiviral agent .
Lead: Stroud; Co-I: Kortemme, Fraser
Lead: Arkin; Co-I:Shoichet, Fraser, Gestwicki
Lead: Renslo; Co-I: Shoichet, Jin
Lead: Agard; Co-I: Verba, Cheng, Stroud, Fraser
Lead: Sali; Co-I: Echeverria, Beltrao, Keiser, Kortemme
Lead: Ott; Co-I: Garcia-Sastre, Towers, Jolly, Vignuzzi, Sesma, Saleh, Martinez, Zuliani-Alvarez, Doudna
Lead: Garcia-Sastre; Co-I: White, Albrecht, Vignuzzi, Saleh, Ott
Lead: Swaney; Co-I: Kaake, Krogan
Lead: Krogan; Co-I: Zuliani-Alvarez, Eckhardt